Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

Exploring novel RNA species for the use of in vivo CAR T-cell generation

EF 2024-25

Résumé
Chimeric antigen receptor (CAR) T-cell therapy is a procedure where T-cells are isolated from a patient, engineered to attack tumour cells, and reintroduced to the patient. Although highly successful against blood cancers, the complex preparation of CAR T-cells and treatment costs surpassing $500,000USD hinder its broadscale implementation. To sidestep manufacturing hurdles, our group and others are generating RNA-carrying lipid nanoparticles (LNPs) capable of modifying T-cells directly in the body. We aim to streamline the LNP facilitated T-cell transfection by using two novel RNA formats to boost CAR T-cell production: circular RNA(circRNA) that can resist degradation and self-amplifying RNA (saRNA) that can replicate itself. Using saRNA and circRNA, we expect to maximize both the generation and duration of CAR T-cells in patients with lower and fewer doses of RNA. To evaluate the feasibility of different RNA formats, we will first engineer various circRNA and saRNA constructs encoding CAR molecules that target B-cell lymphoma. We will then assess the functionality of these constructs in vitro and in vivo, focusing on CAR expression levels and durations as well as their activity against tumour cells. Finally, we will determine the therapeutic utility of saRNA and circRNA in murine lymphoma models: we will establish the optimal schedule (dosage and timing) and evaluate the ability of the novel RNAs to eliminate cancerous B-cells. The generation of CAR T-cells directly in vivo holds great potential to increase the accessibility of CAR T-cell therapies. By utilizing saRNA and circRNA to achieve superior anti-tumour activity, we hope to demonstrate the viability of in vivo CAR T-cell therapies as an affordable alternative for lymphoma and leukemia patients.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529677
Name
Gulhan Ceren
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring novel RNA species for the use of in vivo CAR T-cell generation
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
B-Cell Lymphoma; Cancer Immunotherapy; Car T-Cell Therapy; Circular Rna; In Vivo Car Therapy; Rna-Lnp Technologies; Self-Amplifying Rna
Abstract
Chimeric antigen receptor (CAR) T-cell therapy is a procedure where T-cells are isolated from a patient, engineered to attack tumour cells, and reintroduced to the patient. Although highly successful against blood cancers, the complex preparation of CAR T-cells and treatment costs surpassing $500,000USD hinder its broadscale implementation. To sidestep manufacturing hurdles, our group and others are generating RNA-carrying lipid nanoparticles (LNPs) capable of modifying T-cells directly in the body. We aim to streamline the LNP facilitated T-cell transfection by using two novel RNA formats to boost CAR T-cell production: circular RNA(circRNA) that can resist degradation and self-amplifying RNA (saRNA) that can replicate itself. Using saRNA and circRNA, we expect to maximize both the generation and duration of CAR T-cells in patients with lower and fewer doses of RNA. To evaluate the feasibility of different RNA formats, we will first engineer various circRNA and saRNA constructs encoding CAR molecules that target B-cell lymphoma. We will then assess the functionality of these constructs in vitro and in vivo, focusing on CAR expression levels and durations as well as their activity against tumour cells. Finally, we will determine the therapeutic utility of saRNA and circRNA in murine lymphoma models: we will establish the optimal schedule (dosage and timing) and evaluate the ability of the novel RNAs to eliminate cancerous B-cells. The generation of CAR T-cells directly in vivo holds great potential to increase the accessibility of CAR T-cell therapies. By utilizing saRNA and circRNA to achieve superior anti-tumour activity, we hope to demonstrate the viability of in vivo CAR T-cell therapies as an affordable alternative for lymphoma and leukemia patients.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Gulhan, Ceren
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~